Why the study?
Does the CHA2DS2VASc score predict major adverse cardiac outcomes in ambulatory patients without atrial fibrillation?
Population
468 outpatients without atrial fibrillation or flutter, not using oral anticoagulation. Mean age 64.9 ± 11.3…
Design
Cohort
Follow-up
mean 12 ± 6 months
Key result
A CHA2DS2VASc score ≥6 was associated with a significantly higher risk of major adverse cardiac outcomes in patients without atrial fibrillation (RR 4.2; 95% CI 1.27-13.90).
Authors
Loading...
May aid MACE risk stratification in non-AF outpatients; hypothesis-generating and requires prospective validation.
Cohort (n=468)
Does the CHA2DS2VASc score predict major adverse cardiac outcomes in ambulatory patients without atrial fibrillation?
Effect estimate: RR 4.2 (95% CI 1.27-13.90)
p-value: p=0.035
The CHA2DS2VASc score, traditionally used for atrial fibrillation, can also predict major adverse cardiac outcomes in ambulatory patients without atrial fibrillation.
POLENZ et al. (2015) conducted a cohort in Ambulatory patients without atrial fibrillation (n=468). CHA2DS2VASc score ≥6 vs. Lower CHA2DS2VASc score was evaluated on Major adverse cardiac outcomes (RR 4.2, 95% CI 1.27-13.90, p=0.035). A CHA2DS2VASc score ≥6 was associated with a significantly higher risk of major adverse cardiac outcomes in patients without atrial fibrillation (RR 4.2; 95% CI 1.27-13.90).